Nano-engineered oil droplets can be used to target infectious diseases and provoke specific immune responses to deal with side-effects of broad-spectrum treatments such as chemotherapy, according to a new research.
The researchers at the University of Queensland said the droplets called nanoemulsions can effectively target diseased cells and provoke specific immune responses.The nanoemulsions carry antibodies and protein and can generate an immune response against infectious diseases such as influenza, HIV and malaria.
A paper on the development has been published in the international journal SMALL. Researcher Frank Sainbury said the journal paper provided proof of the precise targeting that could be achieved by nanoemulsions.
- J&K: Students Suffer As Schools Along LOC Forced To Shut Amid Firing
- Jayalalithaa’s Health: AIADMK Women Supporters Continue Special Prayers For CM
- HTC Desire 10 Lifestyle First Look Video
- Fissures Remain Within Samajwadi Party: All You Need To Know
- Big Cheer For Delhi-Noida Commuters, DND Flyway Becomes Toll Free
- PM Modi Meets New Zealand Prime Minister John Key
- Ex-Arunachal CM Kalikho Pul Left Behind “Secret Notes” Before He Was Found Hanging: Rajkhowa
- Big Relief For Former Karnataka CM BS Yeddyurappa: Here’s Why
- Missing For Three Days, JNU Student Found Dead In Hostel Room
- Bigg Boss 10: Review Of October 25 Episode
- Delhi Government’s Rs 200 Crore Riverfront Plan: Find Out More
- School in Jammu & Kashmir’s Bandipore District Set on Fire
- Ajay Devgn On The Making Of Shivaay: Exclusive Interview
- Bodies Of Maoists Killed In Malkangiri Encounter, One Of The Biggest Such Operations
He said it addressed challenges with existing targeted therapies, such as limited drug-carrying capacity and difficulty of manufacture. An ability to target specific cells gives the emulsion the potential to overcome side-effects of broad-spectrum treatments such as chemotherapy, which attacks healthy cells as well as cancerous ones. The nanoemulsion could hold antibodies, releasing them only when targeted cells were found, Sainbury said. “This is about efficient targeting,” he said adding, “Nanoemulsions have a long, safe history in pharmaceutical formulations.”
The research is a collaboration between Anton Middelberg’s Australian Institute for Bioengineering and Nanotechnology research group, UQ’s Diamantina Institute,The Walter and Eliza Hall Institute of Medical Research and Burnet Institute’s Centre for Immunology.